Litigation Details for Law Enforcement Health Benefits Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
✉ Email this page to a colleague
Law Enforcement Health Benefits Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
| Docket | ⤷ Sign Up | Date Filed | 2018-06-20 |
| Court | District Court, S.D. New York | Date Terminated | |
| Cause | 15:1 Antitrust Litigation (Monopolizing Trade) | Assigned To | Alvin K. Hellerstein |
| Jury Demand | Plaintiff | Referred To | |
| Parties | ENDO INTERNATIONAL PLC | ||
| Patents | 6,294,197; 6,395,728 | ||
| Attorneys | Benjamin M. Greenblum | ||
| Firms | Williams & Connolly LLP (DC) | ||
| Link to Docket | External link to docket | ||
Details for Law Enforcement Health Benefits Inc. v. Novartis Pharmaceuticals Corporation (S.D.N.Y. 2018)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2018-06-20 | 1 | Complaint | follow-on patents, U.S. Patent Nos. 6,294,197 (“the ‘197 Patent”) and 6,395,728 (“the ‘728 Patent”), which…, Novartis filed a U.S. Patent Application for the ’197 Patent. In its patent application, Novartis described…exclusivities associated with U.S. Patent No. 5,399,578 (“the ‘578 Patent”); but (2) they would seek final…manufacture generic Exforge® before the ’197 Patent and ’728 Patent expired, Novartis did not file a lawsuit…73 list patents issued after approval of an NDA in the Orange Book in order for the patent to be considered | External link to document |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
